title: An update on emerging drugs for Hodgkin lymphoma.
abstract: BACKGROUND
  Most patients with Hodgkin lymphoma (HL) are cured with modern combined modality first-line treatments. Even ~ 50% of patients with relapsed/refractory HL can be cured with high-dose chemotherapy (HDCT) and autologous stem cell transplantation. However, chemotherapy and radiotherapy cause significant acute and long-term side effects and patients relapsing after HDCT have a dismal prognosis. New drugs are therefore needed to reduce the toxicity of first-line treatments and to increase the efficacy of relapse treatments. Moreover, new drugs are needed for the treatment of older patients with HL because results with current treatments are disappointing.
  
  
  METHODS
  This article discusses promising new drugs for the treatment of classical HL that have been evaluated in the last years. There is a focus on the antibody drug conjugate brentuximab vedotin and its potential for the future treatment of HL. Moreover, data on the histone deacetylase inhibitors panobinostat and mocetinostat, the mammalian target of rapamycin inhibitor everolimus, the Janus kinase 2 inhibitor SB1518 and the immunomodulatory agent lenalidomide are summarized.
  
  
  CONCLUSIONS
  Besides improving the prognosis of relapsed patients, new drugs should be used to replace the most toxic compounds in first-line therapy to reduce acute and long-term toxicities of the treatment.
authors.affiliation: University Hospital of Cologne, Department I of Internal Medicine , Kerpener Str. 62, 50937 Cologne , Germany +49 221 478 97657 ; +49 221 478 98622 ; bastian.von-tresckow@uk-koeln.de.
authors.forename: Bastian
authors.initials: B
authors.lastname: von Tresckow
authors.forename: Volker
authors.initials: V
authors.lastname: Diehl
mesh_terms: D000079963:Brentuximab Vedotin; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D053612:Janus Kinases / Q000037:antagonists & inhibitors; D000077269:Lenalidomide; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D056572:Histone Deacetylase Inhibitors; D018796:Immunoconjugates; D013792:Thalidomide; D000079963:Brentuximab Vedotin; D053612:Janus Kinases; D058570:TOR Serine-Threonine Kinases; D000077269:Lenalidomide
keywords: CD30; Hodgkin lymphoma; Janus kinase 2; brentuximab vedotin; everolimus; lenalidomide; mocetinostat; panobinostat